Combined Transdermal Testosterone Gel and the Progestin Nestorone Suppresses Serum Gonadotropins in Men
Overview
Authors
Affiliations
Context: Testosterone (T) plus progestin combinations are the most promising hormonal male contraceptives. Nestorone (NES), a progestin without estrogenic or androgenic activity, when combined with T may be an excellent candidate for male contraception.
Objective: Our objective was to determine the effect of transdermal NES gel alone or with T gel on gonadotropin suppression.
Design And Setting: The randomized, unblinded clinical trial was conducted at two academic medical centers.
Participants: A total of 140 healthy male volunteers participated.
Interventions: One hundred subjects were randomized initially (20 per group) to apply NES gel 2 or 4 mg, T gel 10 g, or T gel 10 g plus NES gel 2 or 4 mg daily for 20 d. Because only about half of the subjects in T plus NES 4 mg group suppressed serum gonadotropins to 0.5 IU/liter or less (suboptimal suppression), two additional groups of 20 men were randomized to apply daily T gel 10 g plus NES gel 6 or 8 mg.
Main Outcome Variable: Suppression of serum LH and FSH concentrations to 0.5 IU/liter or less after treatment was the main outcome variable.
Results: A total of 119 subjects were compliant with gel applications with few study-related adverse events. NES alone reduced gonadotropins significantly but less than T gel alone. Combined T gel 10g plus NES gel 6 or 8 mg suppressed both serum gonadotropins to 0.5 IU/liter or less in significantly more men than either gel alone.
Conclusion: Transdermal NES gel alone had gonadotropin suppression activity. Combined transdermal NES (6 or 8 mg) plus T gel demonstrated safe and effective suppression of gonadotropins, justifying a longer-term study of this combination for suppression of spermatogenesis.
Management of Male Fertility in Hypogonadal Patients on Testosterone Replacement Therapy.
Fink J, Ide H, Horie S Medicina (Kaunas). 2024; 60(2).
PMID: 38399562 PMC: 10890669. DOI: 10.3390/medicina60020275.
Male contraception: narrative review of ongoing research.
Louwagie E, Quinn G, Pond K, Hansen K Basic Clin Androl. 2023; 33(1):30.
PMID: 37940863 PMC: 10634021. DOI: 10.1186/s12610-023-00204-z.
Service C, Puri D, Hsieh T, Patel D Ther Adv Reprod Health. 2023; 17:26334941221138323.
PMID: 36909934 PMC: 9996746. DOI: 10.1177/26334941221138323.
Post-abortion contraception, an opportunity for male partners and male contraception.
Nguyen B, Jacobsohn T Contraception. 2022; 115:69-74.
PMID: 35870483 PMC: 9561074. DOI: 10.1016/j.contraception.2022.07.004.
Hormonal Male Contraception: Getting to Market.
Page S, Blithe D, Wang C Front Endocrinol (Lausanne). 2022; 13:891589.
PMID: 35721718 PMC: 9203677. DOI: 10.3389/fendo.2022.891589.